Torcetrapib

CAS: 262352-17-0

Ref. 3D-FT15754

Informação sobre produto

• Nome: Torcetrapib
• Sinónimos: (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, 1(2H)-Quinolinecarboxylic acid, 4-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)-, Cp 529414, ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate
• CAS: 262352-17-0

Descrição

Torcetrapib is a drug that inhibits the enzyme DPP-IV, which is responsible for the degradation of a protein called DPP-4. Torcetrapib has been shown to improve atherosclerotic lesions in humans and mice by inhibiting DPP-IV, which prevents the destruction of DPP-4. It also increases levels of a protein called IL-2 receptor, which is involved in immune response and inhibition of tumour growth. Torcetrapib has not been shown to be carcinogenic or mutagenic in animal models. Torcetrapib binds to the cytosolic Ca2+ channel and reduces the activity of this channel, inhibiting cellular proliferation and reducing cholesterol levels in cells. Torcetrapib also has low potency against proteins such as IL-2 receptor and cytosolic Ca2+.

• Marca: Biosynth

Propriedades químicas

• Pureza: Min. 95%